Vitamin K Deficiency

Vitamin K1 (phylloquinone) is dietary vitamin K. Sources include green leafy vegetables (especially collards, spinach, and salad greens), soy beans, and vegetable oils. Dietary fat enhances its absorption. Infant formulas contain supplemental vitamin K. After the neonatal period, bacteria in the gastrointestinal tract synthesize vitamin K, which is absorbed and used by the body.

Vitamin K2 refers to a group of compounds (menaquinones) synthesized by bacteria in the intestinal tract; the amount synthesized does not satisfy the vitamin K requirement.

Vitamin K controls the formation of coagulation factors II (prothrombin), VII, IX, and X in the liver (see table Sources, Functions, and Effects of Vitamins). Other coagulation factors dependent on vitamin K are protein C, protein S, and protein Z; proteins C and S are anticoagulants. Metabolic pathways conserve vitamin K. Once vitamin K has participated in formation of coagulation factors, the reaction product, vitamin K epoxide, is enzymatically converted to the active form, vitamin K hydroquinone.

The actions of vitamin K–dependent proteins require calcium. The vitamin K–dependent proteins, osteocalcin and matrix gamma-carboxy-glutamyl (Gla) protein, may have important roles in bone and other tissues. Forms of vitamin K are common therapy for osteoporosis in Japan and other countries.

Neonates are prone to vitamin K deficiency because of the following:

• The placenta transmits lipids and vitamin K relatively poorly.

• The neonatal liver is immature with respect to prothrombin synthesis.

• Breast milk is low in vitamin K, containing about 2.5 mcg/L (cow’s milk contains 5000 mcg/L).

• The neonatal gut is sterile during the first few days of life.

In adults, vitamin K deficiency can result from

• Fat malabsorption (eg, due to biliary obstruction, malabsorption disorders, cystic fibrosis, or resection of the small intestine)

Coumarin anticoagulants interfere with the synthesis of vitamin K in the intestinal tract and inhibit synthesis of vitamin–K dependent coagulation proteins (factors II, VII, IX, and X) in the liver.

Certain antibiotics (particularly some cephalosporins and other broad-spectrum antibiotics), salicylates, megadoses of vitamin E, and hepatic insufficiency increase risk of bleeding in patients with vitamin K deficiency.

Inadequate intake of vitamin K is unlikely to cause symptoms.

Bleeding is the usual manifestation. Easy bruisability and mucosal bleeding (especially epistaxis, gastrointestinal [GI] hemorrhage, menorrhagia, and hematuria) can occur. Blood may ooze from puncture sites or incisions.

Hemorrhagic disease of the newborn and late hemorrhagic disease in infants may cause cutaneous, GI, intrathoracic, or, in the worst cases, intracranial bleeding. If obstructive jaundice develops, bleeding—if it occurs—usually begins after the fourth or fifth day. It may begin as a slow ooze from a surgical incision, the gums, the nose, or GI mucosa, or it may begin as massive bleeding into the GI tract.

• Usually prolonged prothrombin time (PT) or elevated international normalized ratio (INR) that decreases after phytonadione

Vitamin K deficiency or antagonism (due to coumarin anticoagulants) is suspected when abnormal bleeding occurs in a patient at risk. Blood coagulation studies can preliminarily confirm the diagnosis. PT is prolonged and INR is elevated, but partial thromboplastin time (PTT), thrombin time, platelet count, bleeding time, and levels of fibrinogen, fibrin-split products, and D-dimer are normal.

Some centers can detect vitamin K deficiency more directly by measuring the serum vitamin level. The serum level of vitamin K1 ranges from 0.2 to 1.0 ng/mL in healthy people consuming adequate quantities of vitamin K1 (50 to 150 mcg a day). Knowing vitamin K intake can help interpret serum levels; recent intake affects levels in serum but not in tissues.

More sensitive indicators of vitamin K status, such as PIVKA (protein induced in vitamin K absence or antagonism) and undercarboxylated osteocalcin, are under study.

• Phytonadione

phytonadione is correctly diluted and given slowly, IV replacement can result in anaphylaxis or anaphylactoid reactions.) International normalized ratio (INR) usually decreases within 6 to 12 hours. The dose may be repeated in 6 to 8 hours if INR has not decreased satisfactorily.

phytonadione can be given.

or 0.3 to 0.5 mg/kg IM for infants who weigh ≤ 1500 g is recommended for all neonates within 6 hours of birth to reduce the incidence of intracranial hemorrhage due to birth trauma and of classic hemorrhagic disease of the newborn (risk of increased bleeding 1 to 7 days after birth) (1). It is also used prophylactically before surgery.

The low vitamin K1 content in breast milk can be increased by increasing maternal dietary intake of phylloquinone to 5 mg/day.